- Home
- CATX vs THRD Comparison
CATX vs THRD Comparison
Compare CATX & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- THRD
- Stock Information
- Founded
- CATX 1983
- THRD 2019
- Country
- CATX United States
- THRD United States
- Employees
- CATX N/A
- THRD N/A
- Industry
- CATX Medical/Dental Instruments
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- THRD Health Care
- Exchange
- CATX Nasdaq
- THRD Nasdaq
- Market Cap
- CATX 239.0M
- THRD 238.7M
- IPO Year
- CATX N/A
- THRD 2022
- Fundamental
- Price
- CATX $3.88
- THRD $5.38
- Analyst Decision
- CATX Strong Buy
- THRD Hold
- Analyst Count
- CATX 11
- THRD 3
- Target Price
- CATX $12.90
- THRD $5.00
- AVG Volume (30 Days)
- CATX 934.1K
- THRD 202.4K
- Earning Date
- CATX 08-13-2025
- THRD 08-07-2025
- Dividend Yield
- CATX N/A
- THRD N/A
- EPS Growth
- CATX N/A
- THRD N/A
- EPS
- CATX N/A
- THRD N/A
- Revenue
- CATX $1,471,000.00
- THRD N/A
- Revenue This Year
- CATX N/A
- THRD N/A
- Revenue Next Year
- CATX N/A
- THRD N/A
- P/E Ratio
- CATX N/A
- THRD N/A
- Revenue Growth
- CATX N/A
- THRD N/A
- 52 Week Low
- CATX $1.60
- THRD $3.18
- 52 Week High
- CATX $16.55
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- CATX 50.75
- THRD 44.00
- Support Level
- CATX $3.88
- THRD $5.37
- Resistance Level
- CATX $4.28
- THRD $5.47
- Average True Range (ATR)
- CATX 0.29
- THRD 0.05
- MACD
- CATX -0.06
- THRD -0.02
- Stochastic Oscillator
- CATX 14.61
- THRD 19.44
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.